Request Demo

Last update 03 Apr 2026

Ranibizumab (Genentech)

Last update 03 Apr 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Fab fragment

Synonyms

ACCENTRIX, AMD Fab, AMD-rhuFab-V2

+ [19]

Target

VEGF-A

Action

inhibitors

Mechanism

VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesCongenital Disorders+ [3]

Active Indication

Myopic choroidal neovascularizationDiabetic RetinopathyRetinal Vein Occlusion+ [9]

Inactive Indication

Best Vitelliform Macular Dystrophy, MultifocalBlisterCentral retinal vein occlusion - ischemic+ [34]

Originator Organization

Genentech, Inc.

Active Organization

Hoffmann-La Roche Ltd.

Novartis Pharma KKNovartis Europharm Ltd.

+ [9]

Inactive Organization

Novartis Pharmaceuticals Corp.

Beijing Novartis Pharma Co. Ltd.Novartis Pharmaceuticals UK Ltd.

+ [6]

License Organization

China Medical System Holdings Ltd.

Novartis AG

Genentech, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (30 Jun 2006),

Wet age-related macular degeneration

RegulationBreakthrough Therapy (United States), Priority Review (China), Orphan Drug (Japan), Orphan Drug (Australia), Fast Track (United States)

Structure/Sequence

Sequence Code 103170L

Source: *****

Sequence Code 143622H

Source: *****

436

Clinical Trials associated with Ranibizumab (Genentech)

CTRI/2025/12/099518

/ Not yet recruitingNot ApplicableIIT

Multifocal Electroretinography and contrast sensitivity outcomes with Treat-and-Extend versus Pro Re Nata Ranibizumab for Diabetic macular edema: A Randomized control trial - Nil

Start Date31 Dec 2025

Sponsor / Collaborator-

CTRI/2025/12/098727

/ RecruitingNot ApplicableIIT

Comparison of Systemic Inflammation and OCT-Based Biomarkers in Patients with Diabetic Macular Edema and Their Role in Predicting Treatment Outcomes After Ranibizumab Injection - NIL

Start Date23 Dec 2025

Sponsor / Collaborator-

NCT06847542

/ RecruitingPhase 3

A Phase IIIb, Multicenter, Single-arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration

The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

Start Date27 Nov 2025

Sponsor / Collaborator

Hoffmann-La Roche Ltd.

[+1]

100 Clinical Results associated with Ranibizumab (Genentech)

100 Translational Medicine associated with Ranibizumab (Genentech)

100 Patents (Medical) associated with Ranibizumab (Genentech)

5,304

Literatures (Medical) associated with Ranibizumab (Genentech)

01 May 2026·Value in Health Regional Issues

Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review

Article

Author: Paneerselvam, Ganesh S ; Kenneth, Lee K C ; Wai, Ng J ; Sheng, Lim J

OBJECTIVES:

To evaluate the cost-effectiveness of VEGF inhibitors, ranibizumab, aflibercept, bevacizumab, brolucizumab, pegaptanib, and conbercept for wAMD treatment.

METHODS:

A systematic search was conducted in PubMed, Cochrane, and SpringerLink databases to identify cost-effectiveness analyses and cost-utility analyses related to wAMD treatment. Eligible studies were assessed using Drummond's 10-point checklist to evaluate methodological quality. The extracted data included intervention costs, quality-adjusted life-years, and incremental cost-effectiveness ratios.

RESULTS:

Twenty-two studies met the inclusion criteria. Bevacizumab and brolucizumab were frequently reported as cost-effective alternatives, offering comparable or superior visual outcomes at lower costs than ranibizumab or aflibercept. Pegaptanib was consistently less cost-effective. Findings for ranibizumab versus aflibercept varied by treatment regimen and analytic assumptions. Across studies, cost-effectiveness estimates were influenced by model perspective, time horizon, exclusion of adverse events, and single-eye modeling. A further limitation is that in contexts of non-inferior efficacy, small incremental quality-adjusted life-years differences may artificially inflate incremental cost-effectiveness ratios, potentially overstating the costs relative to benefits.

CONCLUSIONS:

Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments.

06 Mar 2026·MEDICINE

Choroidal neovascularization secondary to punctate inner choroidopathy after resolution of multiple evanescent white dot syndrome: A case report

Article

Author: Wang, Shan ; Li, Zhicheng ; Li, Yanze ; Bai, Jie ; Liu, Yan

Rationale::

White dot syndromes include multiple evanescent white dot syndrome (MEWDS) and punctate inner choroidopathy (PIC), which are rarely reported to coexist or occur sequentially in a single eye. The co-occurrence increases diagnostic complexity, and there are no previous reports of choroidal neovascularization (CNV) secondary to PIC following the resolution of MEWDS. This case report aims to supplement clinical evidence for the pathogenesis and treatment of such sequential ocular diseases.

Patient concerns::

A 42-year-old healthy female presented with blurred vision in her right eye for 3 days initially; 2 months later, her right eye vision worsened further, and 2.5 months after that, she developed blurred vision again with decreased visual acuity.

Diagnoses::

At the first visit, the patient was diagnosed with MEWDS in her right eye based on fundus examination, fundus autofluorescence, fundus fluorescein angiography, visual field test, and optical coherence tomography (OCT) findings. Two months later, she was diagnosed with PIC in the same eye due to new peripapillary yellow-white lesions and corresponding OCT changes. Another 2.5 months later, she was diagnosed with CNV secondary to PIC based on subretinal hemorrhage, abnormal vascular flow on OCT angiography, and fundus fluorescein angiography confirmation.

Interventions::

No treatment was given at the initial diagnosis of MEWDS. After the diagnosis of PIC, the patient received oral prednisone (1 mg/kg per day for 5 days, followed by gradual reduction over 6–8 weeks). For CNV secondary to PIC, intravitreal anti-vascular endothelial growth factor (VEGF) therapy (Ranibizumab, 0.5 mg/0.1 mL, once a month, twice in total) was administered.

Outcomes::

After 2 intravitreal anti-VEGF injections, the best-corrected visual acuity of the patient’s right eye improved to 20/20, fundic hemorrhage resolved, and OCT demonstrated complete resolution of CNV. During 2 years of follow-up, no recurrence of CNV or PIC was observed, and best-corrected visual acuity remained stable at 20/20.

Lessons::

MEWDS and PIC may share common etiological and pathogenetic mechanisms. PIC may develop sequentially after MEWDS in the same eye, and CNV may be a complication of PIC. A combination of oral corticosteroid therapy for PIC and timely intravitreal anti-VEGF injections for secondary CNV can achieve favorable long-term clinical outcomes. Regular follow-up is necessary for patients with MEWDS to monitor for potential progression to PIC and CNV.

01 Mar 2026·EUROPEAN JOURNAL OF OPHTHALMOLOGY

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid

Article

Author: López Herrero, Fernando ; Cabanás Jiménez, Margarita ; Flores Córdoba, Antonio ; Sánchez Vicente, José Luis ; García-Serrano Fuertes, Ricardo ; Suarez Pérez, Jesús ; Romero Martínez, Andrés

Purpose of the research:

This study aimed to evaluate the cost-effectiveness of Brolucizumab in patients with exudative age-related macular degeneration (AMD) and persistent retinal fluid unresponsive to previous therapies, within the context of a real-world clinical practice setting in a Spanish referral hospital. Furthermore, the study examined the probabilities of transitioning between therapies.

Major findings:

A 6-month treatment projection demonstrated that Brolucizumab was not cost-effective compared to Ranibizumab (incremental cost-effectiveness ratio [ICER]: −12.98) and Aflibercept (ICER: −47.64). Conversely, when assessing only drug and administration visit costs, Brolucizumab appeared cost-effective (ICER of 9.14 versus Aflibercept and 35.01 versus Ranibizumab). The increased burden of follow-up costs, which were €348.96 higher than those for Ranibizumab and €174.48 higher than Aflibercept, likely drove the trend towards non-cost-effectiveness. Additionally, the analysis indicated a 43% probability of transitioning to Faricimab within the studied population.

Conclusions:

Brolucizumab was determined to be not cost-effective compared to Ranibizumab and Aflibercept in patients with exudative AMD and persistent retinal fluid, primarily due to a higher number of follow-up visits necessitated by its safety profile. Furthermore, newly observed vitreous opacities and a tendency towards the use of Faricimab were noted.

401

News (Medical) associated with Ranibizumab (Genentech)

19 Mar 2026

·www.chugai-pharm.co.jp

Chugai Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan

Application filed in Japan for the medical device component (ocular implant and ancillary devices) in combination with the Port Delivery Platform when used with ranibizumab In addition to this device application, a filing for the customized ranibizumab formulation (drug product) used in the ocular implant is planned in 2026, with the aim of obtaining approvals for both the device and the drug The ocular implant provides sustained efficacy for 24 weeks (approximately six months) and is expected to enable less frequent dosing and clinic visits, and reduce the burden on patients, their families, and healthcare providers TOKYO, March 19, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that it filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) for the medical device component (implant and ancillary devices; hereafter, the “ocular implant”) of the Port Delivery Platform with ranibizumab when used in combination with of ranibizumab. The application is based on the results from the global Phase III Archway study in patients with neovascular age-related macular degeneration (nAMD), and the global Phase III Pagoda study in patients with diabetic macular edema (DME), both conducted in the US by Roche/Genentech. The Port Delivery Platform with ranibizumab can be commercialized only after obtaining approvals for both the medical device (ocular implant and ancillary devices) and the drug product (a customized ranibizumab 100 mg/ml formulation dedicated to the ocular implant). A regulatory filing for the drug product is planned in 2026 and is expected to include results from the domestic Phase I/II TEIEN study in patients with nAMD and DME, in addition to the Archway and Pagoda studies. “This therapy aims to bring an entirely new treatment option to patients with nAMD and DME by leveraging an innovative ocular implant. Through a mechanism that releases the medicine at a controlled rate, the ocular implant can maintain stable drug levels in the eye over a long period. Treatment can be continued without replacing the implant, which can be refilled using a minimally invasive procedure. While the current standard of care requires intravitreal injections every 4 to 16 weeks, this new approach only requires a refill-exchange once every 24 weeks, potentially reducing the physical and psychological burden associated with frequent clinic visits and procedures. We will work closely with Roche and remain fully committed to obtaining regulatory approval, with the goal of improving patients’ quality of life through continued innovation in ophthalmology,” said Dr. Osamu Okuda, Chugai’s President and CEO. [Reference]Port Delivery System with Ranibizumab Demonstrates Results Phase I/II Trial for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema in Japan (Press release dated November 25, 2025)https://www.chugai-pharm.co.jp/english/news/detail/20251125153001_1204.html Aboutthe Port Delivery Platform with ranibizumabThe Port Delivery Platform is an innovative drug delivery system, comprising an ocular implant designed for the long-term, continuous release of a drug into the eye. 1-4) The platform includes the implant and an insertion device, as well as ancillary devices (initial fill needle, refill needle, and explant tool).The Port Delivery Platform with ranibizumab consists of this implant in combination with a customized 100 mg/ml ranibizumab formulation.5) Ranibizumab is a VEGF inhibitor designed to bind to and inhibit vascular endothelial growth factor-A (VEGF-A). VEGF-A has been shown to reduce angiogenesis and vascular leakage in patients with retinal vascular diseases, including nAMD and DME.1-3,6)Following implantation, the refill formulation is exchanged once every 24 weeks in patients with nAMD and DME. Relative to standard-of-care intravitreal injections administered at 4- to 16-week intervals, this therapy is expected to provide sustained efficacy for approximately six months, enabling reduced dosing frequency and potentially alleviating the burden on patients, their families, and healthcare systems. About neovascular age-related macular degeneration (nAMD)Age-related macular degeneration (AMD) is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading and driving. Neovascular or “wet” AMD (nAMD) is an advanced form of the disease that can cause rapid and severe vision loss if left untreated.7-9) It develops when new and abnormal blood vessels grow uncontrollably under the macula, causing fluid leakage, retinal edema, inflammation, and/or fibrosis.9) Worldwide, around 20 million people are living with nAMD – the leading cause of vision loss in people over the age of 60 – and the condition will affect even more people around the world as the global population ages.7,10,11) About diabetic macular edema (DME)Diabetic macular edema (DME) is estimated to affect approximately 29 million people worldwide and, if left untreated, is a vision-threatening retinal disease that may lead to blindness and reduced quality of life.12-15) DME is a chronic complication of diabetes caused by persistent hyperglycemia; damaged blood vessels leak into the macula, resulting in edema.16,17) The number of people with DME is expected to grow as the prevalence of diabetes increases.18) Sources [PDF 276KB] Contact: For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Naoki Kouzai Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Takayuki Sakurai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp Back

Phase 3

23 Feb 2026

·www.sandoz.com

Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology

MEDIA RELEASE Biosimilar Ranluspec approved by European Commission for treatment of neovascular (wet) age-related macular degeneration (nAMD) and other retinal vascular disorders Around four million people across key global markets live with nAMD; between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy Launch expected second half of 2026; potential to expand access to life-changing treatment option for European patients Basel, February 23, 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today confirmed that the European Commission has granted marketing authorization for Ranluspec1. Ranluspec is developed, manufactured and registered by Lupin and was approved based on the review of a comprehensive data package. Ranluspec is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. Ranluspec has equivalent efficacy and comparable safety to its reference medicine, Lucentis®*2. Around four million people are estimated to have neovascular age-related macular degeneration in France, Germany, Italy, Spain, the UK, the US and Japan3, and between 20% and 35% of people with diabetes in Europe will develop diabetic retinopathy4. The approval paves the way for an expected launch of Ranluspec in the second half of 2026. Claire D’Abreu-Hayling, Chief Scientific Officer, Sandoz, said: “Retinal diseases, including nAMD, place a significant burden on millions of patients, families and caregivers in Europe. The approval of Ranluspec reinforces our commitment to expanding the availability of high‑quality biosimilars and transforming healthcare by ensuring that patients can access these life‑changing treatments.” Today’s announcement builds on the continuing leadership and pioneering legacy Sandoz has established in biosimilars, which began with the introduction of the first biosimilar, Omnitrope® (somatropin), in 2006. It strengthens the company’s position in ophthalmology, following the launch of Afqlir® (aflibercept) in Europe in 2025 and also represents another step towards the overall Sandoz strategic objective of capitalizing on a projected ~USD 320 billion biosimilar-market opportunity over the next 10 years5. Sandoz and Lupin announced a commercial partnership in August 2025 for the development and commercialization of a ranibizumab biosimilar. Under the terms of the agreement, Sandoz holds exclusive commercialization rights for Ranluspec across the European Union, excluding Germany, and semi-exclusive rights in France. Sandoz is commercializing Epruvy® (ranibizumab) in Germany under a separate agreement. * Lucentis® is a registered trademark of Genentech Inc. DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. REFERENCES 1 European Medicines Agency (EMA). Ranluspec® (ranibizumab): Product Details. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ranluspec [Last accessed: February 2026] 2 European Medicines Agency (EMA). Lucentis® (ranibizumab): Prescribing Information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis [Last accessed: February 2026] 3 DRG Clarivate Landscape and Forecast. Dry and Wet Age-Related Macular Degeneration. Report December 2024 4 Eye disease (2024) IDF Europe Site. Available at: https://idf.org/europe/life-with-diabetes/diabetes-related-complications/eye-disease/ [Last accessed: February 2026] 5 Covers US and EU markets (2026–2035). Originator sales and LoE based on internal analysis of data from multiple subscription databases. Biosimilar data accessed in September 2025 ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951 and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. CONTACTS Global Media Relations contacts Investor Relations contacts Global.MediaRelations@sandoz.com Investor.Relations@sandoz.com Alexis Kalomparis +41 792 790285 Craig Marks +44 7818 942 383 Chris Lewis+49 174 244 9501 Tamara Hackl+41 79 790 5217 Gregor Rodehueser+49 170 574 3200 Silvia Siegfried+41 79 795 9061

Drug ApprovalLicense out/in

18 Feb 2026

·www.sandoz.com

Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications

Approved indications now include multiple retinal indications, in addition to previously approved indication of nAMD More than 30 million Americans live with retinal diseases, which can lead to vision loss or blindness1 Enzeevu® is expected to launch in US in Q4 2026 Basel, February 18, 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announced that the US Food and Drug Administration (FDA) has approved an expanded label for Enzeevu® (aflibercept-abzv), to include multiple retinal indications. Enzeevu® was originally approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (nAMD) in August 20242. The most recent approval expands the Enzeevu® label indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), along with the previously approved indication of nAMD. This expansion offers retina specialists a clinically-proven aflibercept biosimilar option to treat more patients across these retinal diseases. Keren Haruvi, President Sandoz North America said: “More than 30 million people in the US are living with retinal diseases that can lead to irreversible vision loss or blindness. With this expanded label, we’re broadening our ability to deliver affordable care to those impacted by these devastating diseases.” Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development. This approval strengthens the company’s position in ophthalmology, following the acquisition of the US biosimilar Cimerli® (ranibizumab-eqrn) in 2024 and the European launch of Afqlir® (aflibercept) in 2025. It also represents another step towards the overall strategic objective of capitalizing on a projected ~USD 320 billion biosimilar market opportunity over the next 10 years3. Enzeevu® is expected to launch in the US in the fourth quarter of 2026, or earlier under certain circumstances. ABOUT ENZEEVU® (AFLIBERCEPT-ABZV) The active ingredient in Enzeevu® is aflibercept. Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF), inhibiting abnormal vessel growth. In patients with neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME), aflibercept is administered into the eye as an intravitreal injection helping to inhibit abnormal blood vessel growth and reduce vascular permeability associated with retinal diseases4. Enzeevu® (aflibercept-abzv) injection, for intravitreal use, is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR) and diabetic macular edema (DME). CONTRAINDICATIONS: Ocular or periocular infection, active intraocular inflammation, hypersensitivity WARNINGS AND PRECAUTIONS: Endophthalmitis, retinal detachments and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment or retinal vasculitis without delay and should be managed appropriately; increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection; there is a potential risk of arterial thromboembolic events following intravitreal use of vascular endothelial growth factor (VEGF) inhibitors ADVERSE REACTIONS: The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters and intraocular pressure increased This is not the complete list of all the safety information for Enzeevu®. Please see full Prescribing Information for Enzeevu®. INDICATIONSCimerli® (ranibizumab-eqrn) injection, for intravitreal use, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD); Macular Edema Following Retinal Vein Occlusion (RVO); Diabetic Macular Edema (DME); Diabetic Retinopathy (DR); Myopic Choroidal Neovascularization (mCNV) CONTRAINDICATIONS: Ocular or periocular infections, hypersensitivity WARNINGS AND PRECAUTIONS: Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection; increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection; there is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors; fatal events occurred more frequently in patients with diabetic macular edema and diabetic retinopathy at baseline, who were treated monthly with ranibizumab compared with control ADVERSE REACTIONS: The most common adverse reactions (reported more frequently in ranibizumab-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP This is not the complete list of all the safety information for CIMERLI®. Please see full Prescribing Information. DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. REFERENCES 1CDC. Vision and eye health surveillance systems. Available at: https://ddt-vehss-cdc-gov.libproxy1.nus.edu.sg/LP?Level1=Age-related+Macular+Degeneration+(AMD)&Level2=AMD+Prevalence&Level3=VEHSS+Modeled+Estimate:+Agerelated+Macular+Degeneration+(AMD)&Level4=Prevalence+of+AMD&LocationId=&DataSourceId=PREV&GSDataSourceId=&GSLocationId=&RiskFactorSubCatId=&IndicatorId=QAMDM~R3_ALL&ShowFootnotes=true&View=NationalChartTable&CompareViewYear=1&CompareId=&CompareId2=&YearId=YR11&ResponseId=R3_ALL&AgeId=AGE40PLUS&GenderId=GALL&RaceId=ALLRACE&RiskFactorId=RFPERS&RiskFactorResponseId=RFTOT&DataValueTypeId=CRDPREV&MapClassifierId=quantile&MapClassifierCount=7&CountyFlag=N [Last Accessed: February 2026] 2 Sandoz. Sandoz receives FDA approval for Enzeevu® (aflibercept-abzv), further strengthening US biosimilar position. Available at: https://www.sandoz.com/sandoz-receives-fda-approval-enzeevutm-aflibercept-abzv-further-strengthening-us-biosimilar/ [Last Accessed: February 2026] 3 Sandoz data on file. 4 Enzeevu®. Prescribing Information. Available at SOK583_BS_A_1.14.1.3_prescribing-information-Enzeevu.pdf: [Last Accessed: February 2026] ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. CONTACTS Global Media Relations contacts Investor Relations contacts Global.MediaRelations@sandoz.com Investor.Relations@sandoz.com Alexis Kalomparis Craig Marks +41 792 790285 +44 7818 942 383 Gregor Rodehueser Silvia Siegfried +49 170 574 3200 +41 79 795 9061 US Media Relations contacts Media.Info@sandoz.com Vicki Crafton +1 201 213 6338

Drug ApprovalAcquisition

100 Deals associated with Ranibizumab (Genentech)

External Link

KEGG	Wiki	ATC	Drug Bank
D05697	Ranibizumab (Genentech)	S01LA04	DB01270

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Myopic choroidal neovascularization	United States	Formycon AG	18 Dec 2025
Diabetic Retinopathy	United States	Genentech, Inc.	06 Feb 2015
Retinal Vein Occlusion	Japan	Novartis Pharma AG	20 Aug 2013
Macular Edema	United States	Genentech, Inc.	22 Jun 2010
Age Related Macular Degeneration	Japan	Novartis Pharma AG	21 Jan 2009
Proliferative retinopathy with diabetes mellitus	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	10 Nov 2008
Retinopathy of Prematurity	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	10 Nov 2008
Vision, Low	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	10 Nov 2008
Choroidal Neovascularization	European Union	Novartis Europharm Ltd.	22 Jan 2007
Choroidal Neovascularization	Iceland	Novartis Europharm Ltd.	22 Jan 2007
Choroidal Neovascularization	Liechtenstein	Novartis Europharm Ltd.	22 Jan 2007
Choroidal Neovascularization	Norway	Novartis Europharm Ltd.	22 Jan 2007
Diabetic macular oedema	European Union	Novartis Europharm Ltd.	22 Jan 2007
Diabetic macular oedema	Iceland	Novartis Europharm Ltd.	22 Jan 2007
Diabetic macular oedema	Liechtenstein	Novartis Europharm Ltd.	22 Jan 2007
Diabetic macular oedema	Norway	Novartis Europharm Ltd.	22 Jan 2007
Retinal vein occlusion-related macular edema	European Union	Novartis Europharm Ltd.	22 Jan 2007
Retinal vein occlusion-related macular edema	Iceland	Novartis Europharm Ltd.	22 Jan 2007
Retinal vein occlusion-related macular edema	Liechtenstein	Novartis Europharm Ltd.	22 Jan 2007
Retinal vein occlusion-related macular edema	Norway	Novartis Europharm Ltd.	22 Jan 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myopia, Degenerative	Phase 3	Japan	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	Austria	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	Canada	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	France	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	Germany	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	Hong Kong	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	Hungary	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	India	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	Italy	Novartis Pharmaceuticals Corp.	01 Oct 2010
Myopia, Degenerative	Phase 3	Latvia	Novartis Pharmaceuticals Corp.	01 Oct 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04503551 (PAVILION, CTgov)	Phase 3	Diabetic macular oedema	174	Intravitreal Ranibizumab 0.5 mg Injection+100 mg/mL Ranibizumab	xhrsjtpbsh = cdtemasmto xfqhlumftj (aqygraswhk, ofnidmnxfy - zmdmwwuuqe) View more	-	25 Nov 2025
EURETINA2025	Not Applicable	Wet age-related macular degeneration	60	Biosimilar Ranibizumab	kpwjgsqqzz(xljcfktrua) = spqyxwhxeh osciaqijdi (dckemehdmc ) View more	Positive	04 Sep 2025
NCT03683251 (Portal, EURETINA2025)	Phase 3	Wet age-related macular degeneration	392	Port Delivery System with ranibizumab (PDS Q24W)	ahkdbuhwua(lmoyjssvgk) = gpnkhucrrs jhehpzwjkk (gnexcitdlk, -9.4 to -5.1) View more	Positive	04 Sep 2025
				Intravitreal ranibizumab 0.5 mg Q4W	ahkdbuhwua(lmoyjssvgk) = jcwdbruvkv jhehpzwjkk (gnexcitdlk, -10.5 to -4.6) View more
NCT04108156 (Pagoda, EURETINA2025)	Phase 3	Diabetic macular oedema	509	PDS Q24W	zonfuawywt(ubqedefrwo) = rhzennefms ihcnsrupnw (schpvwdtpe ) View more	Positive	04 Sep 2025
				monthly ranibizumab 0.5 mg injections	zonfuawywt(ubqedefrwo) = tthvclojcw ihcnsrupnw (schpvwdtpe ) View more
RORE (EURETINA2025)	Not Applicable	Proliferative retinopathy with diabetes mellitus \| Choroidal Neovascularization \| Diabetic macular oedema ... View more	205	Ranibizumab Biosimilar (Oceva) 0.5 mg	nwfkxqlexy(mqdvziyiui) = jrrkgcjxtl izepiucivr (drvuvqngsk ) View more	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Retinopathy of Prematurity	12	Ranibizumab	vmekhxwhxw(jmcevlueun) = There were no significant changes in the mean CFT and IRL thickness at 1 month (p=0.5 and 0.1 respectively). However, there was significant increase in the mean ORL thickness at 1 month (69.9±16, 96.1±25 at baseline and one month respectively, p<0.001), with differentiation (appearance of IS/OS junction ± ELM) in 55.6% of eyes. shmxoydgik (ijgrldeohe ) View more	Positive	04 Sep 2025
SUMMIT (EURETINA2025)	Not Applicable	Wet age-related macular degeneration	46	Port-Delivery System with Ranibizumab	tcjnbizkcu(wsdgonfgva) = pctuiwmpoo zwpmfxxiun (dgikqjecgi ) View more	Positive	04 Sep 2025
NCT00891735 (HARBOR, EURETINA2025)	Phase 3	Age Related Macular Degeneration	417	ranibizumab (T1)	efctxsnygp(nuabjeggik) = hbmesqzpar ufifqdzcoq (tvidvgebfh ) View more	Positive	04 Sep 2025
				ranibizumab (T2/mixed)	efctxsnygp(nuabjeggik) = vkqgivwhtt ufifqdzcoq (tvidvgebfh ) View more
EURETINA2025	Not Applicable	Diabetic macular oedema \| Retinal Vein Occlusion \| Wet age-related macular degeneration	183	Faricimab (Vabysmo)	rgvzjghmre(eggwujlbhj) = pkztxepnrl euaxtvufbs (jargcvifkg, 1 - 12)	Positive	04 Sep 2025
				Ranibizumab biosimilar (Ongavia)	rgvzjghmre(eggwujlbhj) = zrkuyogctg euaxtvufbs (jargcvifkg, 1 - 11)
EURETINA2025	Not Applicable	Diabetic macular oedema \| Wet age-related macular degeneration	201	Ranibizumab	uszntujzcs(vvttdzfyyi): P-Value = 0.003 View more	Positive	04 Sep 2025
				Ximluci

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis